We believe that it is possible to accurately select mHSPC patients who should receive more intensive triplet therapy by considering tumor burden classification as well as high GS (≥ 9), regional lymph node metastasis, and AST/ALT ratio, identified in the present study as prognostic factors. The gene discussed is GPT; the disease is neoplasm.